| Dir : /home/ithome/mail/new/ |
| Server: Linux host100322.itwesthosting.com 3.10.0-1160.144.1.el7.tuxcare.els4.x86_64 #1 SMP Tue Apr 7 08:40:40 UTC 2026 x86_64 IP: 144.91.64.173 |
| Dir : /home/ithome/mail/new/1773418951.M923896P19400.host100322.itwesthosting.com,S=8791,W=8944 |
Return-Path: <isabella.norton@alcpromo.com>
Delivered-To: ithome@host100322.itwesthosting.com
Received: from host100322.itwesthosting.com
by host100322.itwesthosting.com with LMTP
id WPbKNsc5tGnISwAAp0YrwQ
(envelope-from <isabella.norton@alcpromo.com>)
for <ithome@host100322.itwesthosting.com>; Fri, 13 Mar 2026 17:22:31 +0100
Return-path: <isabella.norton@alcpromo.com>
Envelope-to: david.kentera@h1telekom.hr
Delivery-date: Fri, 13 Mar 2026 17:22:31 +0100
Received: from smtp17.alcprom.com ([93.184.68.213]:47092)
by host100322.itwesthosting.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.96.2)
(envelope-from <isabella.norton@alcpromo.com>)
id 1w15HV-000544-1s
for david.kentera@h1telekom.hr;
Fri, 13 Mar 2026 17:22:31 +0100
Received: from [81.89.51.113] (unknown [192.168.190.31])
by smtp17.alcprom.com (Postfix) with ESMTP id 620E827F557
for <david.kentera@h1telekom.hr>; Fri, 13 Mar 2026 17:22:30 +0100 (CET)
DKIM-Filter: OpenDKIM Filter v2.11.0 smtp17.alcprom.com 620E827F557
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=alcpromo.com;
s=2022; t=1773418950;
bh=E8CvPSApigm3a/p6xLyOIR8mAK5CBRPqWvnfoUDnxB0=;
h=From:To:Subject:Date:From;
b=kPkZNZWkvp904Wnn3nul9ckflHkmfJKZPnrPjYvsurId3VDpob+7j5pSBSLM537v5
Z2zRpVwKbfkcZ327OMLNPVNYT65PSuf7iN0l0cA4ELoS/ODzLw9PxXPUk2ZXWz0Frc
7OuDyMRACdJHa85XwKtBWcPW42sY3/4XIsNNZC5LBQ7OVnUEwwl3zoZAb45g/2FabJ
/LrOUKM4Y3Uc01XctroNtYwAw2ug2Uq8uqrGHj3F+UDqgsEkvypq+OwoTzYZD7l72x
4FwNC1COiv+i+5IlFV7fDpTqaRJrVXBCJ4Gq6L3nghvTHX9hzYC4/OxqebkRnziK8i
HZZ4XET27VVow==
From: isabella.norton@alcpromo.com
To: david.kentera@h1telekom.hr
Subject: QPPVs, PV Heads, Safety Leaders: this is your 2026 benchmark event, 12th Annual Summit | Berlin | 6=?UTF-8?B?4oCTNyBNYXkgMjAyNg==?=
Date: 13 Mar 2026 17:22:30 +0100
Message-ID: <20260313172230.BBC0C301FABBEF9E@alcpromo.com>
MIME-Version: 1.0
Disposition-Notification-To: isabella.norton@alcpromo.com
Content-Type: text/html
Content-Transfer-Encoding: quoted-printable
X-Spam-Status: No, score=0.4
X-Spam-Score: 4
X-Spam-Bar: /
X-Ham-Report: Spam detection software, running on the system "host100322.itwesthosting.com",
has NOT identified this incoming email as spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
root\@localhost for details.
Content preview: Dear David, If pharmacovigilance in your organisation is being
pushed harder on inspections, audit readiness, signal detection, vendor oversight,
data integrity, and cross-functional accountability, this is the r [...]
Content analysis details: (0.4 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was
blocked. See
http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block
for more information.
[URIs: allanlloyds.com]
0.0 RCVD_IN_VALIDITY_RPBL_BLOCKED RBL: ADMINISTRATOR NOTICE: The
query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[93.184.68.213 listed in bl.score.senderscore.com]
-0.0 SPF_PASS SPF: sender matches SPF record
0.1 MIME_HTML_ONLY BODY: Message only has text/html MIME parts
0.0 HTML_MESSAGE BODY: HTML included in message
-0.1 DKIM_VALID Message has at least one valid DKIM or DK signature
-0.1 DKIM_VALID_EF Message has a valid DKIM or DK signature from
envelope-from domain
0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily
valid
-0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from
author's domain
0.0 RCVD_IN_VALIDITY_CERTIFIED_BLOCKED RBL: ADMINISTRATOR NOTICE:
The query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[93.184.68.213 listed in sa-trusted.bondedsender.org]
0.5 KAM_NUMSUBJECT Subject ends in numbers excluding current years
X-Spam-Flag: NO
X-From-Rewrite: unmodified, forwarded message
<!DOCTYPE html>
<html><head>
<meta http-equiv=3D"X-UA-Compatible" content=3D"IE=3Dedge">
</head><body style=3D"font-family: Arial, sans-serif; color: #333; line-hei=
ght: 1.6; font-family: Arial; font-size: 10pt;">
<meta http-equiv=3D"X-UA-Compatible" content=3D"IE=3Dedge">
<style>
body { font-family: Arial, sans-serif; color: #333; line-height: 1.6; }
ul { margin-top: 5px; }
</style>
<p>Dear David,<br></p><p>If pharmacovigilance in your organisation is being=
pushed harder on inspections, audit readiness, signal detection, vendor ov=
ersight, data integrity, and cross-functional accountability, this is the r=
oom you need to be in. Join senior pharma leaders at the <a style=3D"text-d=
ecoration: underline;" href=3D"https://pharmacovigilancesummit.com/">12th A=
nnual Risk Management and Pharmacovigilance Summit</a>, taking place 6̵=
1;7 May 2026 in Berlin.<br><br>This is not a generic conference. It is a fo=
cused meeting for the people carrying the pressure: <a href=3D"mailto:enqui=
ry@lloydsconferences.com?subject=3DRequest%20agenda%3A%20Pharmacovigilance"=
>Request the agenda</a><br><ul style=3D"margin-top: 5px; margin-top: 0px; m=
argin-bottom: 0px;"><li>PV leadership</li><li>QPPVs</li><li>Drug Safety and=
Patient Safety heads</li><li>Risk Management leaders</li><li>PV Operations=
, Quality, Compliance and Inspection leads</li><li>Signal Detection, Benefi=
t-Risk, Medical and Clinical Safety teams</li></ul><br>Why attend:<br>=
<ul style=3D"margin-top: 5px; margin-top: 0px; margin-bottom: 0px;"><li>Get=
clear on what regulators are focusing on now</li><li>Learn how leading pha=
rma teams are handling inspection readiness and audit pressure</li><li>Benc=
hmark your approach to signal detection, vendor governance, safety reportin=
g, RWE, and global PV operations</li><li>Leave with practical answers, not =
theory</li></ul><br><strong><u>Some speakers include:</u></strong><br><stro=
ng>Yuri van Geertruij</strong>, Executive Director, Sub-Regional Lead for M=
id-Sized Markets, <strong>Astellas Pharma Europe B.V.</strong><br><strong>W=
ivina De Waele</strong>, Senior Director Europe, Global Markets Patient Saf=
ety, <strong>AstraZeneca AG</strong><br><strong>Claudia Lehmann</strong>, H=
ead of Global Pharmacovigilance Operations, <strong>Boehringer Ingelheim</s=
trong><br><strong>Efstathia Drimyli</strong>, Functional Lead Vendor Oversi=
ght, <strong>Boehringer Ingelheim</strong><br><strong>Alex</strong> <strong=
>Bica</strong>, Global Head Early Development and Translational Safety, <st=
rong>CSL</strong><br><strong>Bjarke Naver</strong>, Director - PV Monitorin=
g and Analysis, <strong>Ferring Pharmaceuticals</strong><br><strong>Enik=
37; Barta-Kondás</strong>, Head of Global PV Operations, <strong>Ged=
eon Richter</strong><br><strong>Ghazi El Masri</strong>, Quality Auditor, S=
enior Manager, <strong>GSK</strong><br><strong>Friederike Höffgen</str=
ong>, Associate Director, Area Safety Head Germany and CE, Local Safety, <s=
trong>Kenvue</strong><br><strong>Signe Neustrup</strong>, Regional Head, Ph=
armacovigilance Quality (PV QA), Western EU, <strong>Novartis</strong><br><=
strong>Marcin Kruk</strong>, Senior Director, Drug Safety Unit Regional Hea=
d, Europe, Africa & Middle East, <strong>Pfizer</strong><br><strong>Ann=
a</strong> <strong>Kończak</strong>, EU QPPV, <strong>Polpharma SA</st=
rong><br><strong>Juliane Koch</strong>, Director, Asset Benefit Risk Lead -=
Benefit Risk and Medical Safety, <strong>UCB</strong><br><strong>Maija Gai=
de</strong>, Pharmacovigilance Manager, Baltics Region, <strong>Viatris<br>=
</strong>and many more....<br><br>Register using the link (early bird disco=
unt 20%): <a href=3D"https://allanlloyds.com/online-event-registration/?eve=
nt=3D577">https://allanlloyds.com/online-event-registration/?event=3D577</a=
> <br><br>For group participation we can tailor something special for =
your organization, let me know the number of participants and I will revert=
=2E<br><br>Best regards,<br>Isabella Norton<br>Alla<span style=3D"font-size=
: 10pt;"></span>n Lloyds Group.<br> Tel: +421 221 021348 <br><p><=
/p>
</body></html>